5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology

Chairs: A. Eniu, RO - C. Zielinski, AT
ESO Masterclass Coordinator: N. Pavlidis, GR


This residential programme has been designed for medical and clinical oncologists, who wish to improve their skills or those who are preparing for the national board or ESMO exam. The programme will expose participants to a full spectrum of issues in clinical and medical oncology from basic science to advanced knowledge of systemic therapy as well as in the multidisciplinary treatment approach. It is intended to cover all major topics of ESMO-ASCO curriculum on medical oncology.

The programme focuses on cancer pathology and molecular biology, pharmacology of anti-cancer drugs and on frequent cancers such as breast, lung, gastro-intestinal, gynaecological and head and neck cancer. Spotlight sessions will provide inside on state of the art approaches in melanoma, sarcoma, thyroid cancer and on palliative care. Furthermore, practical training will be offered in the frame of clinical case presentations, prepared and presented by the participants and faculty for an interactive discussion.

All participants will reside at the Masterclass venue and participation is mandatory throughout the course. At the end of each of the five days a learning self-assessment discussion with the chair of the course will be provided.

LEARNING OBJECTIVES
• To update the knowledge on basic science of clinical and medical oncology
• To enhance the competence and practical performance in systemic therapy of malignancies
• To enhance the competence and practical performance in multidisciplinary cancer care
• To update knowledge and get additional skills in supportive as well as palliative care
• To prepare for the board exam in clinical/medical oncology

THE MASTERCLASS IS:
• A five day residential, educational event
• Full immersion
• Clinically oriented
• Multidisciplinary

MAIN TOPICS
• Cancer biology/pathology
• Cancer genetics
• Pharmacology of anti-cancer drugs
• Breast cancer
• Gastro-intestinal tumours
• Gynaecological tumours
• Head and neck cancers
• Lung cancer and mesothelioma
• Genito-urinary cancers
• Palliative and supportive care
• Haematological malignancies

The Eastern Europe and Balkan Region Masterclass in Medical Oncology is an ESO-ESMO joint event

ORGANISING SECRETARIAT
Dolores Knupfer
European School of Oncology (ESO)
Piazza Indipendenza 2
6500 Bellinzona
ph +41 91 820 09 52
e-mail: dknupfer@eso.net

Applications:
Laura Richetti, lrichetti@eso.net, ph +41 91 8200951

CME ACCREDITATION AND CERTIFICATE
The 5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net
The programme has been granted up to 28 European CME credits (ECMEC). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
The programme is furthermore accredited with 25 ESMO-MORA category 1 points.
Participants will receive their certificate of attendance via e-mail after the event on completion of the evaluation form.

FACULTY (as of May 2018)
C. Antoniotti, Azienda Ospedaliero-Universitaria Pisana, Pisa, IT
J. Beyer, University Hospital Zürich, CH
S. Bosnjak, Institute of Oncology and Radiology of Serbia, Belgrade, RS
E. Brain, Marie Curie Institute, Paris, FR
M.J. Cardoso, Champalimaud Cancer Center, Lisbon, PT
P.G. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
T. Cufer, University Clinic Golnik, SI
A. Eniu, Cancer Institute « I. Chiricuta”, Cluj-Napoca, RO
M.A. Hoda, Medical University Vienna, AT
T. Ivkovic-Kapicl, Oncology Institute of Vojvodina, Sremska Kamenica, RS
D. Jovanovic, Clinical Center of Serbia, Belgrade, RS
I. Kern, University Clinic Golnik, Golnik, SI
V. Kesic, Clinical Centre of Serbia, Belgrade, RS
S. Martin Algarra, University Clinic of Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, ES
J. Mladenovic, Institute for Oncology and Radiology of Serbia, Belgrade, RS
D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY
N. Pavlidis, University Hospital of Ioannina, GR
V. Plešinac, Institute for Oncology and Radiology of Serbia, Belgrade, RS
R. Popescu, Hirslanden Klinik Aarau, CH
C. Sessa, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
C. Sotiriou, Institut Jules Bordet, Brussels, BE
A. Stathis, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
S. Stojanovic- Rundic, Institute for Oncology and Radiology of Serbia, Belgrade, RS
M. Strijbos, AZ Klina, Brasschaat, BE
l. Travado, Champalimaud Cancer Center, Lisbon, PT
J.B. Vermorken, Antwerp University Hospital, Edegem, BE
C. Zielinski, Comprehensive Cancer Center Vienna, AT

 15 June

 16 June

 17 June

 18 June

 19 June

 20 June